Quantcast
Channel: Endpoints News
Viewing all articles
Browse latest Browse all 1687

Ideaya raises $302M; AbbVie to seek approval in giant cell arteritis

$
0
0

Ideaya closes $302.4M raise: The cash came in higher than expected after Ideaya said earlier this week it planned for a $263 million offering. On Monday, Ideaya presented Phase 2 data for a drug designed to treat certain types of urothelial cancer and lung cancer.

AbbVie files new Rinvoq pitch: The company is attempting to get the blockbuster drug approved in giant cell arteritis, which is an autoimmune disease that causes inflammation in large arteries in the neck, arms and temples. If approved, Rinvoq will have to compete against Roche’s Actemra in the disease and potentially Novartis’ Cosentyx. J&J’s Tremfya, meanwhile, notably failed a Phase 3 study in the condition last month.


Viewing all articles
Browse latest Browse all 1687

Trending Articles